Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22893863 | 0.78 | LOXL2 (0.33) | — | |
| SCHEMBL4573872 | 0.74 | SLC6A4 (0.37) | — | |
| SCHEMBL39411 | 0.67 | — | — | |
| SCHEMBL4205669 | 0.65 | — | — | |
| SCHEMBL1756881 | 0.65 | — | — | |
| SCHEMBL9227805 | 0.65 | PDE5A (0.30) | PDE5A | |
| SCHEMBL9625067 | 0.64 | KDM4E (0.50) | — | |
| SCHEMBL2279816 | 0.63 | SLC6A4 (0.35) | — | |
| SCHEMBL3633653 | 0.63 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL8439728 | 0.62 | PDE5A (0.31) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0555153-A1 | Pyrethrinoide esters, derivatives of furan- or thiophenalcohol, process for their preparation and application thereof as pesticides | ROUSSEL UCLAF (FR) | 1993-08-11 | — | — | EP | claimed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| CN-1761657-A | EP4 receptor antagonists | PHARMAGENE LAB LTD (GB) | 2006-04-19 | — | — | CN | disclosed |
| EP-1603893-A1 | EP4 RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192767-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
| US-5405865-A | Pyrethroid esters | ROUSSEL-UCLAF (FR) | 1995-04-11 | — | — | US | disclosed |
| EP-0555153-A1 | Pyrethrinoide esters, derivatives of furan- or thiophenalcohol, process for their preparation and application thereof as pesticides | ROUSSEL UCLAF (FR) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | PDE5A 3583/4885CHKA 2678/4885 |
| US-20040192767-A1 | EP4 receptor antagonists | PTGER4, PTGER1, NR4A1 | PDE5A 3425/4885CHKA 1366/4885 |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, PTGER1 | PDE5A 3670/4885CHKA 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.